A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
Status:
Completed
Trial end date:
2017-05-17
Target enrollment:
Participant gender:
Summary
In this open-label study, eligible and consenting adult patients admitted to the hospital for
critical care that have acute severe anemia, defined as a blood hemoglobin level ≤ 5 g/dL,
but who are unwilling or unable to receive red blood cell (RBC) transfusion, will receive one
or more infusions of SANGUINATE as are deemed necessary by the Investigator for survival of
the acute anemic episode.